Last reviewed · How we verify

NCT04116125: OBSERB

Omitting Biopsy of SEntinel Lymph Node With Radiation After Neoadjuvant Chemotherapy in Breast Cancer (OBSERB) Trial

Status unknown NA Last updated 4 October 2019
What this trial tests

NA trial testing Radiotherapy in Breast Neoplasm Female in 1,380 participants. Status unknown.

Timeline
1 July 2020
Primary endpoint
30 June 2023
30 June 2025

Quick facts

Lead sponsorKyungpook National University Chilgok Hospital
PhaseNA
StatusStatus unknown
Study typeINTERVENTIONAL
Allocationrandomized
Designsingle group
Maskingnone
Primary purposetreatment
Enrollment1,380
Start date1 July 2020
Primary completion30 June 2023
Estimated completion30 June 2025

Drugs / interventions tested

Conditions studied

Sponsor

Kyungpook National University Chilgok Hospital

Who can join

20 and older, female only, with Breast Neoplasm Female or Lymphatic Metastasis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The OBSERB study is a multi-center, non-blinded, pragmatic, parallel, randomized controlled trial in which patients with cT1-3N1 and ycN0 breast cancer.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Radiotherapy

Trials testing the same drug.

Other recruiting trials for Breast Neoplasm Female

Currently open trials in the same condition.

Other Kyungpook National University Chilgok Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04116125.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing